NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

Trial Details

NCT ID
NCT07309289
Phase
PHASE3
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • NALIRIFOX plus targeted therapy
  • FOLFOX plus targeted therapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • ≥18 years old
  • Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma
  • The unresectable stage of metastatic disease has not received any systemic antitumor therapy
  • For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 12 months re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →